Health officials aiming to accelerate the adoption of artificial intelligence in healthcare are engaging in behind-the-scenes efforts to address a growing conflict between state and federal governments regarding technology regulation. While the Trump administration has attempted to reduce regulatory burdens on companies developing health AI and established new payment mechanisms for these technologies, a significant jurisdictional overlap remains unresolved.
The core issue involves the division of authority over AI systems that perform clinical tasks, such as writing prescriptions. States hold the power to regulate the practice of medicine and issue licenses to doctors and other clinicians. However, if an AI system performs these duties without human supervision, the product likely falls under the jurisdiction of the Food and Drug Administration (FDA), which regulates medical devices.
As more states look to test AI in clinical settings, the FDA and the Centers for Medicare & Medicaid Services (CMS) are scrambling to avoid a regulatory logjam. The situation highlights the complexity of integrating autonomous AI tools into a system where state licensing laws and federal device regulations intersect.
Health officials aiming to accelerate the adoption of artificial intelligence in healthcare are engaging in behind-the-scenes efforts to address a growing conflict between state and federal governments regarding technology regulation. While the Trump administration has attempted to reduce regulatory burdens on companies developing health AI and established new payment mechanisms for these technologies, a significant jurisdictional overlap remains unresolved.
The core issue involves the division of authority over AI systems that perform clinical tasks, such as writing prescriptions. States hold the power to regulate the practice of medicine and issue licenses to doctors and other clinicians. However, if an AI system performs these duties without human supervision, the product likely falls under the jurisdiction of the Food and Drug Administration (FDA), which regulates medical devices.
As more states look to test AI in clinical settings, the FDA and the Centers for Medicare & Medicaid Services (CMS) are scrambling to avoid a regulatory logjam. The situation highlights the complexity of integrating autonomous AI tools into a system where state licensing laws and federal device regulations intersect.
Sources: STAT News.